Phase I/II Temozolomide & Hypofractionated XRT for Supratentorial GBM
Trial ID or NCT#
NCT01120639,7,45,17506
Status
NOT RECRUITING
Purpose
The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy plus the FDA-approved chemotherapy drug temozolomide
Official Title
A Phase 1-2 Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme
Investigator(s)
Scott Gerard Soltys
Radiation oncologist
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Contact us to find out if this trial is right for you.
Contact
ccto-office@stanford.edu
650-498-7061
View on ClinicalTrials.gov
